SPRY2 acts as tumor suppressor in BrCa by inhibiting the Ras/Mitogen-Activated Protein Kinase Pathway [46], and in ovarian cancer, through inhibition of Amphiregulin (AREG)-induced cell invasion [47]. Here, WNK2 is linked to neoplasm.